Open access
Open access
Powered by Google Translator Translator

Oncology – Gynecologic

Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma

27 Jan, 2023 | 12:01h | UTC

Computed Tomographic Radiomics in Differentiating Histologic Subtypes of Epithelial Ovarian Carcinoma – JAMA Network Open

 

Commentary on Twitter

 


Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions

24 Jan, 2023 | 14:05h | UTC

Commentary: Meta-Analysis Reaffirms Benefits of O-RADS MRI for Diagnosing Indeterminate Adnexal Lesions – Diagnostic Imaging

Original Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Review | Advances in the diagnosis and early management of gestational trophoblastic disease

19 Jan, 2023 | 14:08h | UTC

Advances in the diagnosis and early management of gestational trophoblastic disease – BMJ Medicine

 


Review | Human papillomavirus vaccination and cervical cancer risk.

16 Dec, 2022 | 13:26h | UTC

Human papillomavirus vaccination and cervical cancer risk – The BMJ

 


Review | Endometrial cancer: molecular classification and future treatments.

16 Dec, 2022 | 13:20h | UTC

Endometrial cancer: molecular classification and future treatments – BMJ Medicine

 

Commentary on Twitter

 


RCT | Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer.

14 Dec, 2022 | 14:44h | UTC

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Treatment With Bevacizumab for 30 Months Provides No Benefit Over 15 Months in Ovarian Cancer – Cancer Network

 

Commentary on Twitter

 


Endocervical sampling in women with suspected cervical neoplasia: a meta-analysis of diagnostic test accuracy studies.

9 Dec, 2022 | 13:12h | UTC

Endocervical sampling in women with suspected cervical neoplasia: a systematic review and meta-analysis of diagnostic test accuracy studies – American Journal of Obstetrics & Gynecology

 


German Guidelines on Sarcoma of the Uterus.

6 Dec, 2022 | 13:50h | UTC

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021) – Geburtshilfe und Frauenheilkunde 


Study | The future risk of cervical precancer among HPV–negative women is increased with a history of HPV–positive results.

1 Nov, 2022 | 12:13h | UTC

Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study – PLOS Medicine

 


The bleeding cervical cancer patient: systematic approach and management.

26 Oct, 2022 | 14:30h | UTC

The Bleeding Cervical Cancer Patient: Systematic Approach and Management – emDocs

 


Secondary prevention of cervical cancer | ASCO resource–stratified guideline update.

6 Oct, 2022 | 13:44h | UTC

Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update – JCO Global Oncology

 


Systematic Review | Impact of residual disease in women with advanced epithelial ovarian cancer after primary surgery.

30 Sep, 2022 | 12:28h | UTC

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery – Cochrane Library

 


ASCO Guideline Update | Poly(ADP-Ribose) Polymerase inhibitors in the management of ovarian cancer.

28 Sep, 2022 | 13:44h | UTC

Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 


Validation of the geriatric vulnerability score in older patients with ovarian cancer.

27 Sep, 2022 | 13:00h | UTC

Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study – The Lancet Health Longevity

 


M-A of randomized trials | Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer.

20 Sep, 2022 | 13:23h | UTC

Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials – ESMO Open

Related:

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial – JAMA Surgery

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – New England Journal of Medicine

 


Systematic Review | Debulking hysterectomy followed by chemoradiotherapy vs. chemoradiotherapy alone for women with locally advanced cancer of the cervix – not enough evidence to guide recommendations.

19 Sep, 2022 | 12:39h | UTC

Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer – Cochrane Library

Summary: Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO (2019) stage IB3/II cervical cancer – Cochrane Library

 


Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

13 Sep, 2022 | 12:56h | UTC

Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer – Cochrane Library

Summary: Ultra-radical (extensive) surgery versus standard surgery to remove tumours in women with advanced ovarian cancer – Cochrane Library

Related Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine

 


Screening for high-risk human papillomavirus using passive, self-collected menstrual blood.

11 Sep, 2022 | 22:41h | UTC

Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood – Obstetrics & Gynecology

Commentary: Pap smears, be gone? Using menstrual blood to detect HPV – Stanford Medicine

 

Commentary on Twitter

 


RCT | Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation.

11 Sep, 2022 | 22:21h | UTC

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial – Journal of Clinical Oncology

Commentary: Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer – OncLive

 


A simple cervicovaginal epigenetic test for screening and rapid triage of women with suspected endometrial cancer: validation in several cohort and case/control sets.

29 Aug, 2022 | 11:58h | UTC

A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets – Journal of Clinical Oncology

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


RCT | HPV self-sampling among long-term non-attenders to cervical cancer screening.

26 Aug, 2022 | 13:27h | UTC

HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial – British Journal of Cancer

 

Commentary on Twitter

 


Endocervical sampling in women with suspected cervical neoplasia: a systematic review and meta-analysis of diagnostic test accuracy studies.

26 Aug, 2022 | 13:18h | UTC

Endocervical sampling in women with suspected cervical neoplasia: a systematic review and meta-analysis of diagnostic test accuracy studies – American Journal of Obstetrics & Gynecology

 


Systematic Review | Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

26 Aug, 2022 | 13:11h | UTC

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer – Cochrane Library

Summary: Hysterectomy with medical management for cervical cancer that has spread to nearby tissues only – Cochrane Library

 


Observational study suggests frequent aspirin use may reduce the risk of ovarian cancer.

25 Aug, 2022 | 11:49h | UTC

Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

Frequent Aspirin Use Tied to Lower Ovarian Cancer Risk – HealthDay

Frequent Aspirin Use Shows Promise for Preventing Ovarian Cancer in Individuals at Higher Risk – University of Utah

 

Commentary on Twitter

 


Long-term follow up of a RCT | Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine.

24 Aug, 2022 | 13:53h | UTC

Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Clinical Unmasking May Cause Increased Rates of High-Grade Cervical Neoplasia From Non–Vaccine Preventable HPV – Cancer Network

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.